3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
5
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
11
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
fludarabine phosphate
7
daratumumab
7
Lenalidomide
7
Bortezomib
7
carfilzomib
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Nivolumab
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
pertuzumab
×
90 days
×
Clear all
No trials found.